Alogliptin May Be Associated With Lower Fracture Risk Compared With Linagliptin, Saxagliptin
The DPP-4 inhibitor alogliptin may be associated with a lower risk for bone fracture compared with linagliptin and saxagliptin.
The Biologics License Application has been resubmitted for Evenity, an investigational treatment for osteoporosis in postmenopausal women at high risk for fracture.
Romosozumab increased spine and hip bone mineral density after 12 months of treatment.
Pain resulting from osteoporotic fractures should be treated with a multimodal approach that includes pharmacological and nonpharmacological strategies.